Dayvigo and NSAIDs (Ibuprofen, Naproxen) Interaction: What You Need to Know

Does Lemborexant Interact with NSAIDs at the Pharmacokinetic Level?

No direct pharmacokinetic interaction exists between lemborexant and ibuprofen or naproxen. Lemborexant is metabolized primarily by CYP3A4, with minor contribution from CYP3A5, and is a mild P-glycoprotein (P-gp) substrate. Neither ibuprofen nor naproxen meaningfully inhibits or induces CYP3A4 or P-gp, so co-administration does not alter lemborexant plasma concentrations in any clinically documented way.

Lemborexant's Metabolic Pathway

The FDA prescribing information for Dayvigo identifies CYP3A4 as the dominant metabolic route for lemborexant [1]. Drugs that would genuinely raise lemborexant exposure include strong CYP3A4 inhibitors such as clarithromycin, itraconazole, and ritonavir. The FDA label states co-use with strong CYP3A4 inhibitors is not recommended because lemborexant area under the curve (AUC) increases by up to 3.8-fold in pharmacokinetic modeling [1].

Ibuprofen is metabolized by CYP2C9 and CYP2C8, not CYP3A4 [2]. Naproxen follows a similar CYP2C9-dominant pathway [2]. Neither drug sits in lemborexant's metabolic lane.

Why NSAIDs Are Still Worth Discussing

The absence of a CYP-level interaction does not mean the combination is trivial. Patients prescribed lemborexant for insomnia often also use over-the-counter ibuprofen or naproxen for pain, headache, or arthritis. Sleep-disordered pain is itself a major driver of insomnia. A clinician who does not address NSAID timing gives the patient incomplete guidance.

Pharmacodynamic Considerations: Sleep Quality and GI Effects

The relevant interaction between Dayvigo and NSAIDs is pharmacodynamic rather than pharmacokinetic. Bedtime NSAID use can generate upper GI discomfort, and that discomfort directly competes with lemborexant's ability to sustain sleep.

How Lemborexant Works

Lemborexant is a competitive antagonist at orexin OX1 and OX2 receptors. Orexin (also called hypocretin) is a neuropeptide that promotes wakefulness; blocking both receptor subtypes reduces the drive to wake. In the SUNRISE-1 trial (N=291, 1-month active treatment), lemborexant 5 mg and 10 mg both produced statistically significant improvements in subjective sleep onset latency compared with placebo and with the active comparator zolpidem tartrate extended-release 6.25 mg (P<0.001 for latency outcomes) [3].

In the 12-month SUNRISE-2 trial (N=949), lemborexant 5 mg and 10 mg maintained superiority over placebo on sleep onset and sleep maintenance endpoints throughout the study period, with no evidence of tolerance development [4].

NSAIDs and Sleep Architecture

Prostaglandins synthesized by COX-1 and COX-2 enzymes modulate body temperature, cortical arousal, and slow-wave sleep depth. Studies using polysomnography have shown that high-dose aspirin and standard doses of ibuprofen reduce slow-wave (N3) sleep by suppressing prostaglandin E2 activity in the preoptic area of the hypothalamus [5]. Naproxen produces a similar pattern.

This means a patient taking naproxen 500 mg at 9 PM alongside lemborexant 10 mg at 10 PM may experience blunted slow-wave restoration even if lemborexant successfully reduces sleep latency. The two drugs work on different systems, but one partially undermines a benefit the other is trying to produce.

GI Irritation as a Sleep Disruptor

NSAIDs inhibit COX-1 in gastric mucosa, reducing the mucus and bicarbonate layer that protects the stomach lining [6]. Bedtime dosing concentrates acid exposure against a less-protected mucosa during the supine position. Symptoms, including epigastric burning, acid reflux, or nausea, can wake a patient who would otherwise stay asleep under the orexin blockade provided by lemborexant.

For patients who must take an NSAID at night, a proton pump inhibitor (PPI) such as omeprazole 20 mg taken 30-60 minutes before the NSAID substantially reduces this risk [6]. Note that PPIs are not CYP3A4 inducers or inhibitors at therapeutic doses, so adding a PPI does not alter lemborexant pharmacokinetics.

Renal Considerations When Combining Dayvigo and NSAIDs

Lemborexant is not nephrotoxic at approved doses and does not require renal dose adjustment in mild to moderate renal impairment per the FDA label [1]. The renal concern in this combination belongs entirely to the NSAID side.

NSAID-Induced Reduction in Renal Prostaglandin Synthesis

The kidneys rely on prostaglandins (particularly PGE2 and PGI2) to maintain afferent arteriolar dilation during states of reduced renal perfusion. NSAIDs block this compensatory vasodilation. In patients with heart failure, cirrhosis, volume depletion, or CKD, even short-course ibuprofen or naproxen can cause a clinically significant drop in GFR [7].

A 2019 analysis published in JASN estimated that short-term NSAID use was associated with a 2-fold increase in acute kidney injury risk among adults over 65 [7]. This does not involve lemborexant at all. However, the clinical scenario is relevant because insomnia is disproportionately prevalent in older adults, many of whom already have reduced renal reserve.

Monitoring Guidance

For patients over 65 or with a baseline eGFR <60 mL/min/1.73 m² who are taking both lemborexant and a chronic NSAID:

• Check serum creatinine and potassium at baseline and after 2-4 weeks of concurrent use.
• Prefer acetaminophen 500-1,000 mg at bedtime as an alternative analgesic when the pain indication allows it. Acetaminophen does not affect renal prostaglandins at standard doses.
• If NSAID use is unavoidable, use the lowest effective dose for the shortest duration.

Bleeding Risk: Is There an Additive Concern?

Lemborexant has no effect on platelet function or coagulation pathways. The FDA label reports no clinically significant effect on bleeding time in pharmacodynamic studies [1]. NSAIDs, by contrast, reversibly inhibit COX-1-mediated thromboxane A2 synthesis in platelets, extending bleeding time for the duration of the dosing interval.

The clinical takeaway: any bleeding risk from the combination is attributable to the NSAID alone, not to additive pharmacology between lemborexant and the NSAID. Patients on anticoagulants (warfarin, apixaban, rivaroxaban) or antiplatelet agents (clopidogrel) who are also prescribed lemborexant face a real bleeding hazard if they add ibuprofen, but lemborexant is not part of that hazard.

CNS Depression: The More Clinically Significant Drug Interaction Category for Dayvigo

While the lemborexant-NSAID combination carries minor risk, the interactions clinicians should prioritize involve CNS depressants. The AASM 2023 clinical practice guideline on pharmacologic treatment of chronic insomnia recommends careful co-prescribing review before combining any hypnotic, including dual orexin receptor antagonists (DORAs), with other CNS depressants [8].

Drugs That Meaningfully Interact with Lemborexant

The FDA label for Dayvigo identifies the following categories as genuinely impactful [1]:

• Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole, ritonavir): avoid co-use; AUC increases up to 3.8-fold.
• Moderate CYP3A4 inhibitors (fluconazole, diltiazem, verapamil): limit lemborexant to 5 mg; monitor for excess sedation.
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort): co-use is not recommended; lemborexant AUC may drop by over 80%, rendering the dose therapeutically inadequate.
• Other CNS depressants (alcohol, benzodiazepines, opioids, first-generation antihistamines): additive sedation and psychomotor impairment the next morning.

NSAIDs do not appear on any of these interaction lists because they do not engage lemborexant's pharmacologic mechanisms.

Next-Morning Impairment

Lemborexant's half-life of approximately 17-19 hours means residual drug is present during waking hours [1]. The SUNRISE-1 trial measured next-morning driving performance using a driving simulation. At 10 mg, lemborexant produced statistically significant impairment the morning after the first dose compared with placebo, though impairment was not significantly different from placebo after night 8 [3]. Ibuprofen and naproxen do not add to this psychomotor effect.

Special Populations: Pregnancy, Lactation, and Elderly Patients

Elderly Patients

The AASM 2023 guideline notes that older adults metabolize CYP3A4 substrates more slowly on average due to reduced hepatic blood flow and CYP enzyme activity [8]. This means lemborexant plasma levels may run higher in a 72-year-old than in a 40-year-old at the same dose. Starting at 5 mg in patients over 65 is the standard recommendation.

NSAIDs in the elderly carry a separate American Geriatrics Society Beers Criteria warning. The 2023 Beers Criteria designates oral non-COX-selective NSAIDs as "potentially inappropriate" for adults 65 and older unless alternatives are inadequate, due to GI and renal risks [9]. This Beers flag does not reference lemborexant, but it reinforces the message that nighttime NSAID use in older insomnia patients deserves review on its own merits.

Pregnancy

Lemborexant is Pregnancy Category not assigned (post-2014 labeling); the FDA label states data are insufficient to establish risk in pregnant women [1]. NSAIDs carry a known risk of premature closure of the ductus arteriosus if used at or after 20 weeks gestation; they are contraindicated in the third trimester [2]. Prescribers should evaluate both drugs independently for pregnant patients.

Lactation

The FDA label notes that lemborexant is present in rat milk; human data are absent [1]. For breastfeeding patients who need both a sleep aid and an analgesic, acetaminophen is the preferred analgesic given its established lactation safety profile.

Patient Counseling Points: Practical Guidance for Dayvigo + NSAID Co-Use

The following framework covers what to tell a patient who asks about taking ibuprofen or naproxen while on Dayvigo:

1. Timing matters. If the NSAID is for pain that does not need nighttime coverage, take it earlier in the day (morning or midday) to reduce the chance of nocturnal GI symptoms interfering with sleep.

2. Take NSAIDs with food or milk. Even a small amount of food reduces COX-1-mediated gastric irritation. This is true regardless of lemborexant use.

3. Acetaminophen is often a better bedtime analgesic. For headache or mild musculoskeletal pain at bedtime, acetaminophen 500-1,000 mg avoids all NSAID-related GI, renal, and platelet concerns and does not interact with lemborexant.

4. Know the ceiling. Ibuprofen above 1,200 mg/day over-the-counter or naproxen above 660 mg/day OTC exceeds the self-treatment threshold. Prescription-strength NSAIDs need a clinician's review, particularly in the context of chronic insomnia and ongoing lemborexant use.

5. Report new GI symptoms. Any new epigastric pain, black or tarry stools, or blood in vomit warrants stopping the NSAID and contacting a clinician before the next lemborexant dose.

6. Alcohol amplifies lemborexant sedation. This is not an NSAID interaction, but patients combining a sleep aid with OTC pain medications are often the same patients who use alcohol to aid sleep. Combining alcohol with lemborexant 10 mg produces additive CNS depression [1].

Summary of Interaction Severity by Category

| Interaction Category | Exists? | Severity | Action | |---|---|---|---| | CYP3A4 pharmacokinetic (lemborexant levels) | No | None | No dose adjustment | | P-gp transport alteration | No | None | No dose adjustment | | Pharmacodynamic: sleep architecture (N3 suppression by NSAIDs) | Yes | Minor | Time NSAID dose earlier in day | | GI irritation disrupting sleep | Yes | Minor to moderate | Food with NSAID; consider PPI if needed | | Renal prostaglandin suppression | NSAID-only | Moderate in high-risk patients | Monitor eGFR; prefer acetaminophen | | Platelet/bleeding | NSAID-only | Moderate if on anticoagulants | Review full med list | | CNS sedation | No | None | No additional caution from NSAIDs |